ESGIC-PLUS Drug Patent Profile
When do Esgic-plus patents expire, and when can generic versions of Esgic-plus launch?
Esgic-plus is a drug marketed by Mikart and is included in two NDAs.
The generic ingredient in ESGIC-PLUS is acetaminophen; butalbital; caffeine. There is one drug master file entry for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the acetaminophen; butalbital; caffeine profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ESGIC-PLUS?
- What are the global sales for ESGIC-PLUS?
- What is Average Wholesale Price for ESGIC-PLUS?
Summary for ESGIC-PLUS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 8 |
| Patent Applications: | 122 |
| DailyMed Link: | ESGIC-PLUS at DailyMed |
US Patents and Regulatory Information for ESGIC-PLUS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mikart | ESGIC-PLUS | acetaminophen; butalbital; caffeine | CAPSULE;ORAL | 040085-001 | Mar 28, 1996 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mikart | ESGIC-PLUS | acetaminophen; butalbital; caffeine | TABLET;ORAL | 089451-001 | May 23, 1988 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
